Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for intermediate-high risk prostate cancer diagnosis: The SAMURAI Trial
- Conditions
- Prostate CancerCancer - Prostate
- Registration Number
- ACTRN12618001307291
- Lead Sponsor
- Australian Urology Associates
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 50
(1) adult 18 years of age and above with new transperineal/transrectal biopsy diagnosed prostate cancer
(2) male sex
(3) eligible for definitive treatment with radical prostatectomy (based on age, medical co-morbidities, past history, disease progression/severity, life expectancy or other factors), as determined by the treating urologist
(4) eligible to undergo a Ga68 PSMA PET/CT scan as part of standard clinical care
(5) biopsy diagnosed cancer is intermediate risk prostate cancer or higher (greater than or equal to Gleason 3+4=7 or Grade Group 2)
(6) Signed, written, informed consent
(1) <18 years old
(2) low risk prostate cancers (Less than or equal to Gleason 3+3=6 or Grade Group 1)
(3) previously diagnosed prostate cancers (includes treated and untreated prostate cancers)
(4) ineligible for definitive treatment with radical prostatectomy due to age, medical co-morbidities, past history, disease progression/severity, life expectancy or other factors as determined by the treating urologist
(5) contraindications to injection of Gallium 68 labelled PSMA radiotracer, magnetic resonance imaging and PET/CT
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method